Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
An announcement from Autolus Therapeutics ( (AUTL) ) is now available.
On June 26, 2025, Autolus Therapeutics held its Annual General Meeting where all nine proposed resolutions were passed. Key resolutions included the adoption of the 2024 Annual Report, approval of the Directors’ remuneration report and policy, re-appointment of Ernst & Young LLP as auditors, re-election of Dr. R Iannone and Dr. R Rao as Directors, and the approval of the Employee Share Purchase Plan.
The most recent analyst rating on (AUTL) stock is a Buy with a $13.00 price target. To see the full list of analyst forecasts on Autolus Therapeutics stock, see the AUTL Stock Forecast page.
Spark’s Take on AUTL Stock
According to Spark, TipRanks’ AI Analyst, AUTL is a Neutral.
The overall stock score of 53 is largely influenced by weak financial performance due to ongoing operational losses and cash flow issues. Despite a strong technical analysis and positive earnings call sentiment, the company’s financial challenges weigh heavily on the score. The valuation is also impacted by the negative P/E ratio, highlighting the need for improved profitability.
To see Spark’s full report on AUTL stock, click here.
More about Autolus Therapeutics
Autolus Therapeutics is a biopharmaceutical company focused on the development of next-generation, programmed T cell therapies for the treatment of cancer.
Average Trading Volume: 2,327,706
Technical Sentiment Signal: Sell
Current Market Cap: $617.4M
Learn more about AUTL stock on TipRanks’ Stock Analysis page.